Darolutamide with androgen deprivation therapy for treating hormone sensitive metastatic prostate cancer: a cost-comparison technology appraisal
Darolutamide with androgen deprivation therapy for treating hormone sensitive metastatic prostate cancer: a cost-comparison technology appraisal
This report is a critique of the company’s submission (CS) to NICE from Bayer ondarolutamide with androgen deprivation therapy (ADT) for treating hormone sensitive metastatic prostate cancer (mHSPC). It identifies the strengths and weakness of the CS.
Southampton Health Technology Assessments Centre
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
2025
Woods, Lois
8149aa11-7664-4052-a18b-98f7bde83180
Takahashi, Marcia
fa084efd-dc46-4325-8fc9-d3f6d1f8b5d0
Kalita, Neelam
da42f168-a3cc-44c9-bafb-2801ff57914b
Shepherd, Jonathan
dfbca97a-9307-4eee-bdf7-e27bcb02bc67
Woods, Lois, Takahashi, Marcia, Kalita, Neelam and Shepherd, Jonathan
(2025)
Darolutamide with androgen deprivation therapy for treating hormone sensitive metastatic prostate cancer: a cost-comparison technology appraisal
Southampton Health Technology Assessments Centre
73pp.
Record type:
Monograph
(Project Report)
Abstract
This report is a critique of the company’s submission (CS) to NICE from Bayer ondarolutamide with androgen deprivation therapy (ADT) for treating hormone sensitive metastatic prostate cancer (mHSPC). It identifies the strengths and weakness of the CS.
Text
Darolutamide ID6452 EAG report
- Version of Record
More information
Published date: 2025
Identifiers
Local EPrints ID: 507417
URI: http://eprints.soton.ac.uk/id/eprint/507417
PURE UUID: 1b58e0db-58fa-4b83-a013-07c1ef60cc87
Catalogue record
Date deposited: 09 Dec 2025 17:36
Last modified: 10 Dec 2025 02:59
Export record
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics